PB1904: TRIAL IN PROGRESS: A PHASE III STUDY OF ASCIMINIB VS AN INVESTIGATOR-SELECTED TKI IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)

• T. Hughes,
• J. Cortes,
• N. Takahashi,
• R. Larson,
• G. Issa,
• F. Bombaci,
• N. Ramscar,
• S. Kapoor,
• S. Ifrah,
• A. Hochhaus

Affiliations

T. Hughes

1 SA Pathology and South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, Australia

J. Cortes

2 Georgia Cancer Center, Augusta, United States of America

N. Takahashi

3 Akita University, Akita City, Japan

R. Larson

4 The University of Chicago, Chicago

G. Issa

5 The University of Texas MD Anderson Cancer Center, Houston, United States of America

F. Bombaci

6 CML Advocates Network, Turnin, Italy

N. Ramscar

7 Novartis Pharma AG, Basel, Switzerland

S. Kapoor

8 Novartis Pharmaceuticals Corporation, East Hanover, United States of America

S. Ifrah

9 Novartis Pharma AG, Paris, France

A. Hochhaus

10 Universitätsklinikum Jena, Jena, Germany